 |
| The U.S. is the largest pharmaceutical market in the world, and the Affordable Care Act has brought new opportunities, by increasing the pool of insured people. Launching drugs in the U.S. offers huge prospects for biopharma companies to gain returns on their significant R&D investment, including those companies working in the orphan drug arena. |
| Join our webinar to learn more about payer needs and how to maximize patient value of your product. Listen to speakers from Pierre Fabre and Quintiles and join their discussion when they review the learnings of a European specialty biopharma company, which successfully launched in the U.S. market. |
|
| Understand the aspects of breaking into the U.S. for small biotechs: |
|
|
• |
|
Filing with the FDA |
|
|
• |
|
Gaining approval from the FDA |
|
|
• |
|
Obtaining licensing stocking and distribution |
|
| |
• |
|
Conducting market research |
|
| |
• |
|
Managed care strategy, achieve Formulary coverage, access and reimbursement |
|
| |
• |
|
Learn how a specialty European based biopharma company successfully launched an orphan drug in the U.S. market |
|
|
|
|
| Presenters: |
|
Randolph Carpio
Vice President, Managed Markets, Quintiles
Joe Bonaccorso
Vice President, Pierre Fabre |
|
| Moderator: |
|
Michael Christel
Editor, Pharmaceutical Executive |
|
|
|
|
|
|
Questions:
Contact Sara Barschdorf at sbarschdorf@advanstar.com
|
|
US Toll free: 1 866 267 4479
US Direct: +1 973 850 7571
Non US: +44 203 564 4649
www.quintiles.com
commercial@quintiles.com
|
|
|
|
|
